ADC Bio

ADC Bio Aims to Provide New Antibody-Drug Conjugates. The company's biotechnology platform has developed a patented Lock-Release technology for the development and manufacturing of antibody-drug conjugates (ADC) cancer treatment groups, specifically targeting and killing tumor cells, enabling doctors to treat patients with antibody-drug conjugates and antibody-based cancer therapies.